Insulin Resistance in Women With Prolactinoma

Prolactin is suggested to influence insulin resistance, but scarce data is available on the metabolic profile of patients with prolactinoma.

The purpose of the protocol was to evaluate cardiovascular disease risk factors in women with prolactinoma treated with dopamine agonists and to study the influence of disease control and anthropometry on their metabolic profile.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prolactinoma Adenoma Brain Diseases Central Nervous System Diseases Dyslipidemias Endocrine Gland Neoplasms Endocrine System Diseases Glucose Metabolism Disorders Hyperinsulinism Hyperlipidemia Hyperlipidemias Hyperpituitarism Hyperprolactinemia Hypothalamic Diseases Insulin Resistance Lipid Metabolism Disorders Metabolic Diseases Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Nervous System Diseases Nutritional and Metabolic Diseases Pituitary Diseases Pituitary Neoplasms

Age range

18 year–48 year

Sex eligibility

Female

Study type

Observational

Primary location

Clementino Fraga Filho University Hospital

Rio de Janeiro, Brazil

About this study

A cross-sectional study was performed in non-obese premenopausal women with prolactinoma treated with dopamine agonists evaluated regarding glucose, insulin, Homeostasis Model Assessment (HOMA), lipid profile, C reactive protein (CRP), body mass index (BMI), waist circumference, prolactin, estradiol, testosterone, and sex hormone binding globulin (SHBG). They were compared with control women of similar age and BMI distribution.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Prolactinoma
Female gender
Premenopausal

Exclusion criteria

Obesity (BMI ≥ 30 kg/m²)
Diabetes mellitus
Hypertension
GH deficiency
Hypothyroidism
Primary hypogonadism
Adrenal insufficiency
Pituitary surgery

Sponsors and collaborators

Lead sponsor

Universidade Federal do Rio de Janeiro

Other

Registry information

Official study title

Insulin Resistance and Lipid Profile in Non-Obese Women With Prolactinoma Treated With Dopamine Agonists

Important dates

Study start: 2004
Study completion: 2006
First posted: Jun 1, 2007
Registry last updated: Jun 1, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed